Renaud Du Pasquier
Overview
Explore the profile of Renaud Du Pasquier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Disanto G, Schaedelin S, Oechtering J, Lorscheider J, Galbusera R, Finkener S, et al.
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315457.
PMID: 40017897
Background: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these...
2.
Theiler K, Bronchain M, Grouzmann E, Duflon S, Hirt L, Du Pasquier R, et al.
Front Neurosci
. 2025 Jan;
18():1505727.
PMID: 39840012
We report a patient with autonomic dysfunction following acute SARS-CoV-2 infection, presenting progressively worsening severe orthostatic hypotension to the point where she could no longer sit or stand. The patient...
3.
Baumgartner T, Di Liberto G, Loser V, Vicino A, Theaudin M, Castro-Jimenez M, et al.
Rev Med Suisse
. 2025 Jan;
21(900-1):59-62.
PMID: 39812289
In 2024, therapeutic and diagnostic advancements are shaping the field of neurology. Three new drugs show promise for treating myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A new classification for...
4.
Gayer M, Xu Z, Hodel F, Preisig M, Strippoli M, Vollenweider P, et al.
Brain Behav Immun Health
. 2024 Dec;
42:100896.
PMID: 39624483
Given the association of Epstein-Barr virus (EBV) with subjective perception of fatigue and demyelination in clinical conditions, the question about potential subclinical effects in the adult general population remains open....
5.
Benkert P, Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez J, et al.
Ann Neurol
. 2024 Oct;
PMID: 39411917
Objective: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy...
6.
Stolting A, Vanden Bulcke C, Borrelli S, Bugli C, Du Pasquier R, van Pesch V, et al.
Ann Clin Transl Neurol
. 2024 Oct;
11(12):3137-3151.
PMID: 39382072
Objective: Previous studies reveal heterogeneity in terms of paramagnetic rim lesions (PRL) associated tissue damage. We investigated the physiopathology and clinical implications of this heterogeneity. Methods: In 103 MS patients...
7.
Greselin M, Lu P, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, et al.
Bioengineering (Basel)
. 2024 Aug;
11(8).
PMID: 39199815
The detection of contrast-enhancing lesions (CELs) is fundamental for the diagnosis and monitoring of patients with multiple sclerosis (MS). This task is time-consuming and suffers from high intra- and inter-rater...
8.
Courlet P, Spaggiari D, Cavassini M, Du Pasquier R, Saldanha S, Buclin T, et al.
Clin Mass Spectrom
. 2024 Aug;
8:8-20.
PMID: 39192990
Nucleoside reverse transcriptase inhibitors (NRTIs) have been the first class of antiretroviral drugs used against HIV infection. Despite NRTI-free regimens have been eagerly sought over the years in an effort...
9.
Thevoz G, Phillips N, Rebeaud J, Lim-Dubois-Ferriere P, Revaz A, Gauthier-Jaques A, et al.
Mult Scler Relat Disord
. 2024 Aug;
90:105808.
PMID: 39128162
Background: Environmental and lifestyle factors are associated with an increased risk of Multiple Sclerosis (MS). Metabolic syndrome (MetS) contributes to systemic inflammation, which is associated with poorer MS disease evolution....
10.
Mathias A, Perriot S, Jones S, Canales M, Bernard-Valnet R, Gimenez M, et al.
Front Immunol
. 2024 Aug;
15:1419712.
PMID: 39114659
Background And Objectives: Up to 46% of patients with presumed autoimmune limbic encephalitis are seronegative for all currently known central nervous system (CNS) antigens. We developed a cell-based assay (CBA)...